Post Offer Free
Foshan Jiazhinuo Biotechnology Co.,Ltd
Foshan Jiazhinuo Biotechnology Co.,Ltd

China Dabrafenib (Tafinlar) CAS 1195765-45-7 for Skin Cancer GSK2118436 manufacturer

4th

Gold Index: 91165

You are here: home  > Pharmaceuticals  > Dabrafenib (Tafinlar) CAS 1195765-45-7 for Skin Cancer GSK2118436

Dabrafenib (Tafinlar) CAS 1195765-45-7 for Skin Cancer GSK2118436 

Price: 1.0 USD 
Payment Terms: T/T,WU,Money Gram;Bitcoin 
Place of Origin: Guangdong, China (Mainland) 
inquire skype
Add to My Favorites
HiSupplier Escrow
Share |

Product Detail

Means of Transport: Ocean,Land,Air
Packing: 25kg/Drum
Production Capacity: 1000kg/month
Delivery Date: 4days

CAS NO: 1195765-45-7
MF: C23H20F3N5O2S2
MW: 519.5624096
EINECS: 200-366-3
Appearance: White to slightly yellowish-white crystalline
Assay: 99%min

Dabrafenib Profile


Product name: Dabrafenib 

Synonyms: Dabrafenib;N-[3-[5-(2-Amino-4-pyrimidinyl)-2-(tert-butyl)-4-thiazolyl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide;Dabrafenib free base(GSK2118436A);Dabrafenib(GSK2118436);GSK2118436A;Dabrafenib (GSK2118436);Dabrafenib KB-57246;Debrafenib API

CAS NO: 1195765-45-7

MF: C23H20F3N5O2S2

MW: 519.5624096

EINECS: 200-366-3

Appearance: White to slightly yellowish-white crystalline

Assay: 99%min

Storage: Shading, confined preservation


Dabrafenib Description


Dabrafenib (trade name Tafinlar, GSK2118436) is a drug for the treatment of cancers associated with a mutated version of the gene BRAF. Dabrafenib acts as an inhibitor of the associated enzyme B-Raf, which plays a role in the regulation of cell growth. Dabrafenib has clinical activity with a manageable safety profile in clinical trials of phase 1 and 2 in patients with BRAF(V600)-mutated metastatic melanoma.


The Food and Drug Administration initially approved dabrafenib as a single agent treatment for patients with BRAF V600Emutation-positive advanced melanoma on May 30, 2013.Clinical trial data demonstrated that resistance to dabrafinib and other BRAF inhibitors occurs within 6 to 7 months.To overcome this resistance, the BRAF inhibitor dabrafenib was combined with the MEK inhibitor trametinib.On January 8, 2014, the FDA approved this combination of dabrafenib and trametinib for BRAF V600E/K-mutant metastatic melanoma.


Dabrafenib Application


Dabrafenib is used to treat a certain type of melanoma (a type of skin cancer) that cannot be treated with surgery or that has spread to other parts of the body. Dabrafenib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps stop the spread of cancer cells.


Ms. Karry
skype Ms. Karry
Sales Manager
Tel: 86-0757-82035343
Mobile: 86- 188 2631 2629
Contact to this supplier

Didn't find what you're looking for? Post Buying Lead or contact HiSupplier Customer Service Center  for help!

Related Search

Find more related products in following catalogs on Hisupplier.com

Other products from this supplier

Company Info

Foshan Jiazhinuo Biotechnology Co.,Ltd [China (Mainland)]


Business Type:Manufacturer, Trading Company
City: Foshan
Province/State: Guangdong
Country/Region: China (Mainland)

Karry:   skype
Karry:   qq

You May Like: